# GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Source: https://onco.cc/trials/nct04652076/  
OnCo record `nct04652076` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab and Carboplatin in endometrial cancer and cervical cancer, run by NETRIS Pharma, active and no longer recruiting.

## Summary

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab is a phase 1/2 interventional study registered as NCT04652076 by NETRIS Pharma, with 240 participants enrolled, started 2020-12-14 and due to reach its primary completion in 2025-10-30. Interventions recorded: NP137, Pembrolizumab, Paclitaxel and Carboplatin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04652076
- Phase: 1/2
- Setting: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination with Carboplatin Plus Paclitaxel And/or Pembrolizumab in Patients with Locally Advanced/metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/relapsing After At Least One Prior Systemic Chemotherapy.
- Sponsor: NETRIS Pharma
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT04652076: https://clinicaltrials.gov/study/NCT04652076

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [NP137](https://onco.cc/drugs/np137/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04652076.json